Vincent Restivo, MD
Ophthalmology · Cedar Park, TXNPI 1811967821
Payments from drug & device makers
Across 241 payments — averaging $3843.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$465K
- Bausch Health US, LLC$337K
- Bausch & Lomb Americas Inc.$52K
- Kala Pharmaceuticals, Inc.$44K
- Novartis$26K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$466
- plus $2K from 16 others
Across 4 payments — averaging $17,866 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$71K
What the payments were for
- Consulting fees$84316%
- Travel & lodging$1282%
- Food & beverage$4,35682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $465,489 |
| Bausch Health US, LLC | 41 | $337,377 |
| Bausch & Lomb Americas Inc. | 15 | $51,726 |
| Kala Pharmaceuticals, Inc. | 15 | $43,836 |
| Novartis | 10 | $25,738 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $466 |
| Biotissue Holdings Inc. | 8 | $322 |
| Alcon | 16 | $301 |
| Sun Pharmaceutical Industries Inc. | 7 | $193 |
| Eyevance Pharmaceuticals LLC | 1 | $189 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $121 |
| Ocular Therapeutix, Inc. | 5 | $115 |
| Amgen(2 entities) | 7 | $112 |
| Glaukos Corporation | 1 | $106 |
| Harrow Eye, LLC | 3 | $74 |
| Oyster Point Pharma, Inc. | 2 | $44 |
| Kowa Research Institute, Inc. | 1 | $34 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Rxsight Inc | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVISC50$800
- Flarex$189
- Tecnis Multifocal Family of 1-piece IOLS$121
- LUMIGAN$120
- iStent inject W$106
How this compares
$926,336 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $121,378 |
| LumiganBimatoprost | 146 | $90,263 |
| Cyclosporine | 72 | $60,787 |
| XiidraLifitegrast | 26 | $39,211 |
| CequaCyclosporine | 14 | $8,955 |
| Loteprednol Etabonate | 37 | $7,256 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $6,277 |
| Latanoprost | 342 | $4,804 |
| Bepotastine Besilate | 23 | $3,281 |
| Travoprost | 15 | $2,539 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,163 |
| Timolol Maleate | 182 | $2,027 |
| Brimonidine Tartrate | 62 | $1,814 |
| Fluorometholone | 16 | $1,381 |
| Prednisolone Acetate | 17 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $465,489 | $217,917242 claims |
| Bausch & Lomb Americas Inc.Xiidra | $51,726 | $39,21126 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $193 | $8,95514 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $466 | $7,25637 claims |
| AlconSimbrinza | $301 | $2,16311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Cedar Park
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.